Ranbaxy Laboratories announced that the company received US FDA approval for its abbreviated new drug application to market and manufacture Ramipril capsules of 5 mg and 10 mg strengths.
Ramipril is indicated in patients of 55 years or older, who are at high risk of developing a major cardiovascular event or diabetes that is accompanied by at least one other cardiovascular risk factor to reduce the risk of myocardial infarction, stroke or death from cardiovascular causes.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.